| Entry |
|
|---|
| Name |
Lenvatinib mesylate (USAN);
Lenvatinib mesilate (JAN);
Lenvima (TN) |
|---|
| Product |
|
|---|
| Formula |
C21H19ClN4O4. CH4SO3
|
|---|
| Exact mass |
522.0976
|
|---|
| Mol weight |
522.9586
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
Transporter substrate
DG01665 ABCB1 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG01362): | D09920<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Thyroid cancer [DS: H00032] Renal cell carcinoma [DS: H00021] Hepatocellular carcinoma [DS: H00048] Endometrial cancer [DS: H00026] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX08 Lenvatinib
D09920 Lenvatinib mesylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Lenvatinib
D09920 Lenvatinib mesylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D09920 Lenvatinib mesylate (USAN); Lenvatinib mesilate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
FGFR family
FGFR
D09920 Lenvatinib mesylate (USAN) <JP/US>
VEGFR family
VEGFR1 (FLT1)
D09920 Lenvatinib mesylate (USAN) <JP/US>
VEGFR2 (KDR)
D09920 Lenvatinib mesylate (USAN) <JP/US>
VEGFR3 (FLT4)
D09920 Lenvatinib mesylate (USAN) <JP/US>
RET family
RET
D09920 Lenvatinib mesylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09920
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09920
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09920
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09920
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09920
Drug transporters
D09920
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 35
1 C8y C 12.8800 -22.4700
2 C8y C 12.8800 -23.8700
3 C8x C 14.1400 -24.5700
4 C8y C 15.3300 -23.8700
5 C8y C 15.3300 -22.4700
6 C8x C 14.1400 -21.7700
7 C8y C 16.5200 -24.5700
8 C8x C 17.7800 -23.8700
9 C8x C 17.7800 -22.4700
10 N5x N 16.5200 -21.7700
11 O2a O 16.5200 -25.9700
12 C8y C 17.7800 -26.6700
13 C8x C 17.7800 -28.0700
14 C8y C 18.9700 -28.7700
15 C8y C 20.1600 -28.0700
16 C8x C 20.1600 -26.6700
17 C8x C 18.9700 -25.9700
18 O2a O 11.6900 -21.7700
19 C5a C 11.6900 -24.5700
20 N1a N 10.5000 -23.8700
21 O5a O 11.6900 -25.9700
22 X Cl 18.9700 -30.1700
23 N1b N 21.4200 -28.7700
24 C5a C 22.6100 -28.0700
25 N1b N 23.8000 -28.7700
26 O5a O 22.6100 -26.6700
27 C1a C 10.5000 -22.4000
28 C1y C 24.9900 -28.0700
29 C1x C 26.3900 -28.0700
30 C1x C 25.6900 -26.8100
31 C1a C 21.2100 -23.1700
32 S4a S 22.6100 -23.1700
33 O1d O 24.0100 -23.1700
34 O1d O 22.6100 -21.7700
35 O1d O 22.6100 -24.5700
BOND 37
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 7 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 1 18 1
21 2 19 1
22 19 20 1
23 19 21 2
24 14 22 1
25 15 23 1
26 23 24 1
27 24 25 1
28 24 26 2
29 18 27 1
30 25 28 1
31 28 29 1
32 28 30 1
33 30 29 1
34 31 32 1
35 32 33 1
36 32 34 2
37 32 35 2
|
|---|
